


**Amendments to the Claims:**

The following listing of claims replaces all prior versions, and listings, of claims in the application:

**Listing of Claims:**

1. (currently amended) A method of treating myocardial damage secondary to myocardial infarction in a patient who has suffered a myocardial infarction, said method comprising administering to said patient who has suffered the myocardial infarction an amount of 4-chloro-5-[(4,5-dihydro-1H-imidazol-2-yl)-amino]-6-methoxy-2-methylpyrimidine corresponding to formula I:



or a physiologically compatible salt thereof effective to inhibit myocardial damage secondary to myocardial infarction.

2. (original) A method according to claim 1, wherein the compound of Formula I or physiologically compatible salt thereof is administered for treating myocardial damage secondary to myocardial infarction in acute myocardial infarction.

3. (original) A method according to claim 1, wherein the compound of Formula I or physiologically compatible salt thereof is administered for postmyocardial infarction management.

4. (original) A method according to claim 3, wherein the compound of Formula I or physiologically compatible salt thereof is administered for treating myocardial damage secondary to myocardial infarction in the management of chronic postmyocardial infarction patients.

5. (original) A method according to claim 1, for treating myocardial damage secondary to myocardial infarction, wherein an amount of the compound of Formula I or physiologically compatible salt thereof that is effective in promoting recovery or rehabilitation of myocardial status is administered in admixture with at least one pharmaceutical adjuvant or carrier.